ARTICLE | Clinical News

Zebinix eslicarbazepine acetate regulatory update

October 24, 2016 7:00 AM UTC

EMA’s CHMP recommended a label expansion for Zebinix eslicarbazepine acetate from Bial-Portela to include its use as adjunctive therapy in adolescents and children ages >6 with partial-onset seizures with or without secondary generalization. The voltage-gated sodium channel blocker is approved in adults. Zebinix will also be available as an oral suspension; it is already available as tablets...